123 filings
Page 4 of 7
8-K
ig4hpg411a iac0r
4 Mar 22
Departure of Directors or Certain Officers
4:02pm
8-K
36sz 7gy5
10 Jan 22
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
8:07am
8-K
4rlg dg5v8rvp0lqj
10 Nov 21
ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors
4:21pm
8-K
6euhx 2cy7
8 Nov 21
ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update
4:16pm
8-K
sliihcuaaw
7 Oct 21
ORIC Pharmaceuticals Presents Initial Clinical Data from
4:06pm
8-K
541afoyd 7p
18 Aug 21
Other Events
6:07am
8-K
wfc7 gzshd13
16 Aug 21
ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
4:41pm
8-K
glrsd37
10 Aug 21
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
4:16pm
8-K
4lrp jrr9olz18
12 Jul 21
Other Events
5:05pm
8-K
bj98cyl736hk6j
8 Jul 21
ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
6:05am
8-K
qm2khnjc
21 Jun 21
ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
4:06pm
8-K
j4rvywo pj
6 May 21
Entry into a Material Definitive Agreement
5:10pm
424B5
bnz6k7
6 May 21
Prospectus supplement for primary offering
5:01pm
S-3ASR
y4mdsr2
6 May 21
Automatic shelf registration
4:33pm
8-K
iwhb f4v4ri1cg9xa
6 May 21
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
4:10pm
DEFA14A
2sh1hp9t9
26 Apr 21
Additional proxy soliciting materials
6:15am
DEF 14A
vtvr5k03fr0b 8mc79l
26 Apr 21
Definitive proxy
6:05am